Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-IT201 in advanced solid tumors
NCT06613152Phase 1Not yet recruiting
- Sponsor
- Qingdao Sino-Cell Biomedicine Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
01
Overview
Phase 1, open-label, single-arm trial of HS-IT201 in solid tumor (advanced stage), sponsored by Qingdao Sino-Cell Biomedicine Co., Ltd. Primary endpoints: Adverse Events at 12 months and Serious Adverse Events at 12 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
HS-IT201
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06613152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613152.